Zuellig Pharma announces the appointment of John Graham as its new CEO. John will run the US$13 billion business and lead the team across our 13 markets in Asia.

John joined Zuellig Pharma in 2018 to oversee the development and growth of our Commercial Solutions business, spearheading the growth of its marketing, sales, business development and regulatory services. He takes over the helm from former CEO John Davison who retired at the end June 2020.

John has over three decades of industry experience in biotech, pharmaceuticals, strategy consulting and healthcare investment banking across Europe, Asia, Latin America and the United States. He previously held various senior global leadership positions at Aventis, Genzyme and Ernst & Young, as well as the role of CEO at Menarini Asia-Pacific based in Singapore, where he established the company’s Asia-Pacific commercial footprint.

“John brings with him a strong track record of strategic and operational leadership through the various global roles he has held. In his time with Zuellig Pharma, John has also driven unparalleled success in the Commercial Solutions business. We look forward to working closely with him to continue to transform the organisation and execute our exciting growth plans,” said Patrick Davies, Chairman of Zuellig Pharma.

“Over the next few years, my goal is to transform Zuellig Pharma into a major integrated healthcare business that is indispensable to industry stakeholders and has a major impact on society. Together, we will continue to pursue our mission to make healthcare more accessible through providing world-class, innovative solutions to our partners and customers in distribution, commercial and digital technology,” said John.

John assumed his new role on 1 July this year and is based in our headquarters in Singapore.